5 Key Takeaways

• 1

  A blood test measuring anti-Müllerian hormone (AMH) may help identify premenopausal women with breast cancer unlikely to benefit from chemotherapy.

• 2

  The analysis of the phase 3 RxPONDER trial established that some postmenopausal women can receive endocrine therapy without chemotherapy.

• 3

  AMH concentrations below 10 pg/mL indicated low ovarian reserve and no measurable benefit from adding chemotherapy to endocrine therapy.

• 4

  Approximately 21 percent of premenopausal participants younger than 55 years had AMH below the 10-pg/mL threshold.

• 5

  The authors called for optimized laboratory methods to measure AMH at low concentrations and further validation in clinical trials.